CDEK
← All drugs Report issue

allogeneic lymphocytes

Cell therapyexperimental

Clinical trial activity

126 trials · 100 clinical orgs · 0 marketing orgs

Phase 1
42
Phase 2
91
Phase 3
4
Phase 4
0

Earliest trial started Feb 1, 1995 (NCT00002778)

Timeline

1990s

  1. Jan 1, 1995

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 1997

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • allogeneic lymphocytes
  • donor lymphocyte
  • donor lymphocytes

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06252870Phase 2Jul 18, 2024University of Angers, University of Nantes, University of Western Brittany
NCT06297629Phase 2Jul 1, 2024Astex Pharmaceuticals, Inc., University of Texas at Houston
NCT06158100Phase 1Feb 28, 2024AbbVie, University of Miami
NCT05772273N/AMar 15, 2023Hengrui Therapeutics, Inc., Soochow University
NCT04886206Phase 1Sep 30, 2021University of Nantes
NCT04857645Phase 2Jun 22, 2021Astex Pharmaceuticals, Inc., Groupe Francophone des Myelodysplasies, Paris Diderot University
NCT05009719Phase 1/Phase 2 (Phase 2)Apr 1, 2021Pavlov First Saint Petersburg State Medical University
NCT04055844Phase 2Sep 30, 2019Incyte, University of Minnesota, University of Rochester, Washington University in St. Louis
NCT03982992Phase 2Jun 1, 2019Amgen, Ludwig Maximilians University
NCT03597321Phase 2Jan 31, 2019Institut Paoli-Calmettes
NCT04687982N/ANov 13, 2018Istituto Clinico Humanitas - Rozzano (MI), Italy
NCT03662087Phase 2/Phase 3 (Phase 3)Oct 31, 2018Southern Medical University
NCT03597594Phase 1/Phase 2 (Phase 2)Sep 30, 2018St. Jude Children's Hospital
NCT03374332Phase 2Jun 30, 2018Brown University, Pfizer, Rhode Island Hospital
NCT03413800Phase 2Feb 12, 2018Celgene, Centre de Commercialisation en Immunothérapie du Cancer, Ciusss de L'Est de l'Île de Montréal
NCT03297528Phase 2Nov 1, 2017Peking University
NCT02587871Phase 2Jun 1, 2017National Cancer Institute (NCI), University of Southern California
NCT03032783Phase 2Jan 31, 2017Thomas Jefferson University
NCT03035422N/AJan 1, 2017Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
NCT02684162Phase 2Jun 1, 2016Astex Pharmaceuticals, Inc., University of Texas at Houston
Showing 20 of 126 trials
Page 1 / 7

Organizations

Research & Development (100)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government59931995
University of WashingtonAcademic/Hospital181831997
Thomas Jefferson UniversityAcademic/Hospital131021998
National Institutes of Health (NIH)Government6121997
University of California, San FranciscoAcademic/Hospital6531999
Rutgers UniversityAcademic/Hospital5332001
University of Texas at HoustonAcademic/Hospital5512003
Johns Hopkins UniversityAcademic/Hospital4331995
National Heart, Lung, and Blood Institute (NHLBI)Government4221997
University of MinnesotaAcademic/Hospital4412004
Astex Pharmaceuticals, Inc.For profit3012016
Cancer Research UKAcademic/Hospital3312008
CelgeneFor profit3012013
Institut Paoli-CalmettesAcademic/Hospital3112002
Stanford UniversityAcademic/Hospital3222012
University of LondonAcademic/Hospital3022009
University of NantesAcademic/Hospital3322011
University of North Carolina at Chapel HillAcademic/Hospital3212001
Harvard UniversityAcademic/Hospital2122001
Lund UniversityAcademic/Hospital2222005
100 organizations
Page 1 / 5